Zobrazeno 1 - 10
of 486
pro vyhledávání: '"Vlado Perkovic"'
Autor:
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S. Bajaj, G. B. John Mancini, Norman C. Wong, April Slee, Fernando G. Ang, Wally Rapattoni, Brendon L. Neuen, Clare Arnott, Vlado Perkovic, Kenneth W. Mahaffey
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 3 (2024)
Background This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention). Methods and Results This was a pooled participant‐level analysis of
Externí odkaz:
https://doaj.org/article/859194b3dcd443bf875f3d7f0a7d9fcb
Autor:
Brendon L. Neuen, Min Jun, James Wick, Sradha Kotwal, Sunil V. Badve, Meg J. Jardine, Martin Gallagher, John Chalmers, Kellie Nallaiah, Vlado Perkovic, David Peiris, Anthony Rodgers, Mark Woodward, Paul E. Ronksley
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 43, Iss , Pp 100988- (2024)
Summary: Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of kidney failure and death in patients with chronic kidney disease (CKD) but are underused. We evaluated the number of patients with CKD in Australia that would
Externí odkaz:
https://doaj.org/article/557ba8a7348b4e93955ae1a6aab13157
Autor:
Dana V. Rizk, Brad H. Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Hernán Trimarchi, Vlado Perkovic, Matthias Meier, Dmitrij Kollins, Olympia Papachristofi, Alan Charney, Jonathan Barratt
Publikováno v:
Kidney International Reports, Vol 8, Iss 5, Pp 968-979 (2023)
Introduction: Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically bi
Externí odkaz:
https://doaj.org/article/e273eb3d888049e0b8276461498c3f08
Autor:
Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J.L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernán Trimarchi, Vlado Perkovic
Publikováno v:
Kidney International Reports, Vol 8, Iss 5, Pp 1043-1056 (2023)
Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults wit
Externí odkaz:
https://doaj.org/article/25a866cd50534c7d82716666703db077
Autor:
Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo. J. L. Heerspink
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided by multivariable pre
Externí odkaz:
https://doaj.org/article/9ab201997da946b29c0687e277525199
Autor:
Robert A. Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta E. Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George Bakris, Tara I. Chang, Hiddo J. L. Heerspink, Meg J. Jardine, Kenneth W. Mahaffey, Bruce Neal, Carol Pollock, Min Jun, Anthony Rodgers, Vlado Perkovic, Brendon L. Neuen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 13 (2023)
Background Sodium glucose cotransporter‐2 inhibitors reduce systolic blood pressure (SBP), but whether they affect SBP variability is unknown. There also remains uncertainty regarding the prognostic value of SBP variability for different clinical o
Externí odkaz:
https://doaj.org/article/3075bc7abafb43759d117a083ff6e2ac
Autor:
Bernard Zinman, Bruce Neal, George L Bakris, Vlado Perkovic, Meg J Jardine, Kris Rogers, Jie Yu, Adeera Levin, Dick de Zeeuw, Hong Zhang, Kenneth W Mahaffey, Clare Arnott, Rajiv Agarwal, Gian Luca Di Tanna, Carol Pollock, David C Wheeler, Christopher P Cannon, David M Charytan, Hiddo J Lambers Heerspink, Norman Rosenthal
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 11, Iss 3 (2023)
Introduction Relationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain.Research design and methods We analyzed 4395 individuals with prebaseline and po
Externí odkaz:
https://doaj.org/article/83663dfd99b5429482efb801e4aa82d8
Autor:
Brendon L Neuen, Aminu K Bello, Adeera Levin, Meaghan Lunney, Mohamed A Osman, Feng Ye, Gloria E Ashuntantang, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Sara Davison, Mohammad Ghnaimat, Paul Harden, Vivekanand Jha, Kamyar Kalantar-Zadeh, Peter G Kerr, Scott Klarenbach, Csaba P Kovesdy, Valerie Luyckx, Shahrzad Ossareh, Jeffrey Perl, Harun Ur Rashid, Eric Rondeau, Emily J See, Syed Saad, Laura Sola, Irma Tchokhonelidze, Vladimir Tesar, Kriang Tungsanga, Rumeyza Turan Kazancioglu, Angela Yee-Moon Wang, Chih-Wei Yang, Alexander Zemchenkov, Ming-Hui Zhao, Kitty J Jager, Fergus J Caskey, Vlado Perkovic, Kailash K Jindal, Ikechi G Okpechi, Marcello Tonelli, John Feehally, David C Harris, David W Johnson
Publikováno v:
PLOS Global Public Health, Vol 3, Iss 2, p e0001467 (2023)
National strategies for addressing chronic kidney disease (CKD) are crucial to improving kidney health. We sought to describe country-level variations in non-communicable disease (NCD) strategies and CKD-specific policies across different regions and
Externí odkaz:
https://doaj.org/article/03a15b13ef9c48d9a1d39f2ea65948e6
Autor:
Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 16 (2022)
Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In
Externí odkaz:
https://doaj.org/article/46cbfff7ef724eea8154c25524ea230a
Autor:
Jie Yu, Clare Arnott, Brendon L. Neuen, Hiddo L. Heersprink, Kenneth W. Mahaffey, Christopher P. Cannon, Sadiya S. Khan, Abigail S. Baldridge, Sanjiv J. Shah, Yuli Huang, Chao Li, Gemma A. Figtree, Vlado Perkovic, Meg J. Jardine, Bruce Neal, Mark D. Huffman
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 1482-1493 (2021)
Abstract Aims The CANVAS Program identified the effect of canagliflozin on major adverse cardiovascular events (MACE) differed according to whether participants were using diuretics at study commencement. We sought to further evaluate this finding re
Externí odkaz:
https://doaj.org/article/851c1009f53f4b14acb1ca781b58c180